ArticleJournal of neurology2026
Genetic spectrum and clinical features of PMP22 point mutations in Japanese Charcot-Marie-Tooth disease.
Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundPMP22 duplications cause Charcot-Marie-Tooth disease (CMT), whereas PMP22 deletion results in hereditary neuropathy with liability to pressure palsies (HNPP). Although PMP22 point mutations can cause a spectrum of neuropathies, including hereditary motor and sensory neuropathy (HMSN) I, congenital hypomyelinating neuropathy, HMSN III, and HNPP, they are rare, and their features in Japanese patients have not been well characterized. Therefore, we compared the genetic, clinical, and electrophysiological characteristics of patients with PMP22 point mutations.
methodsThis multicenter study enrolled 3352 Japanese patients clinically suspected of having inherited peripheral neuropathies/CMT who underwent fluorescence in situ hybridization, multiplex ligation-dependent probe amplification, gene panel sequencing, or whole-exome analysis between 1995 and 2024. Clinical and electrophysiological data were obtained from patients' medical records.
resultsThe study enrolled 30 patients with PMP22 point mutations and 57 patients with PMP22 duplications. Among the point mutation cases, 24 distinct variants were detected, including four novel variants (p.T23K, p.R95Sfs*16, p.M111R, and p.P144R). Two splice-site variants (c.78 + 3G > T and c.79-2A > G) were associated with HNPP, whereas the others were associated with polyneuropathy. Compared with patients with PMP22 duplications, those with point mutations experienced earlier disease onset (0 vs. 35.0 years), were less likely to have a family history (14.3% vs. 61.7%), and were less frequently ambulatory (12/28 vs. 50/54). Upper limb compound muscle action potentials were more frequently undetectable in patients with point mutations (18/25 vs. 1/50).
conclusionsPMP22 point mutations-associated polyneuropathies were characterized by earlier disease onset and more severe effects than duplications, highlighting the broad clinical spectrum of PMP22-related neuropathies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.